Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia.

Clinica chimica acta; international journal of clinical chemistry - 1 Dec 2008

Willrich Maria Alice V, Hirata Mario H, Genvigir Fabiana D V, Arazi Simone S, Rebecchi Ivanise M M, Rodrigues Alice C, Bernik Marcia M S, Dorea Egidio L, Bertolami Marcelo C, Faludi André A, Hirata Rosario D C

Abstract excerpt

BACKGROUND: The cytochrome P450 isoenzyme 3A5 (CYP3A5) has an important role on biotransformation of xenobiotics. CYP3A5 SNPs have been associated with variations on enzyme activity that can modify the metabolism of several drugs. METHODS: In order to evaluate the influence of CYP3A5 variants on response to lowering-cholesterol drugs, 139 individuals with hypercholesterolemia were selected. After a wash-out...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atorvastatin
Share to Black People

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholesterol, LDL

Share to Cytochrome P-450 CYP3A

Share to Heptanoic Acids

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hypercholesterolemia

Share to Pyrroles

Source

Identifiers

PMID: 18727922
DOI: 10.1016/j.cca.2008.07.032

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia.PMID 18727922Read ↗

CYP3A4*1B and CYP3A5*3 SNPs significantly impact the response of Egyptian candidates to high-intensity statin therapy to atorvastatin.Semantic proximity Read ↗

Association of cytochromes P450 3A4*22 and 3A5*3 genotypes and polymorphism with response to simvastatin in hypercholesterolemia patients.Semantic proximity Read ↗

Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients.Semantic proximity Read ↗

Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population.Semantic proximity Read ↗

Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?Semantic proximity Read ↗

Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia.Semantic proximity Read ↗

Evaluation of genetic polymorphism of CYP3A5 in normal healthy participants from western India - A cross-sectional study.Semantic proximity Read ↗

Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects.Semantic proximity Read ↗

Genetic polymorphisms of the drug-metabolizing enzyme cytochrome P450 3A5 in a Uyghur Chinese population.Semantic proximity Read ↗

Lipid-lowering response to statins is affected by CYP3A5 polymorphism.Semantic proximity Read ↗

Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort.Semantic proximity Read ↗

CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.